HB553 would require most health insurance coverage in Hawaii to include biomarker testing when medically supported for diagnosis, treatment, management, or monitoring of a disease or condition. The mandate applies to individual and group accident and health or sickness policies, hospital and medical service plan contracts, mutual benefit society plans, health maintenance organizations, and Medicaid managed care plans. Coverage must be available for tests supported by FDA labeling, FDA-approved drug indications and warnings, Medicare coverage determinations, and nationally recognized clinical practice guidelines or consensus statements.
The bill also requires insurers and plan issuers to provide coverage in a way that minimizes disruptions in care, including avoiding unnecessary repeat biopsies, and to maintain a clear exception-request process for patients and providers if coverage is restricted. Cost-sharing is allowed, but only on terms no less favorable than those applied to other covered medical services. Insurers and mutual benefit societies must notify policyholders and members about the new coverage by the end of 2026, and the Department of Human Services must seek any needed Medicaid state plan amendments for the Medicaid managed care portion.
Impact
HB553 would add new mandatory-benefit provisions to Hawaii insurance law by creating biomarker testing coverage requirements in chapters 431 and 432 and by incorporating those benefits into the HMO required-benefits statute in chapter 432D. It would also extend the reimbursement requirement to Medicaid managed care health plans, subject to federal approval of state plan amendments. The bill expressly excludes limited benefit health insurance and defines key terms such as biomarker, biomarker testing, clinical practice guidelines, and consensus statements.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text and report title, the measure appears to be framed as a patient-access and coverage-expansion bill aimed at modernizing insurance benefits for precision medicine and medically necessary testing. The overall tone of the legislation is pro-coverage and pro-access.
Contention
The main likely points of contention are the cost and administrative impact on insurers and health plans, the breadth of the required coverage, and how insurers will interpret the medical-scientific evidence standards used to justify testing. Another possible issue is the exception process and whether it gives plans enough flexibility to manage utilization while still ensuring timely access for patients and providers. Medicaid implementation may also raise questions because it depends on CMS approval and state plan amendments.